MarketPulse

pharmaceutical market

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Bispecific Antibodies Poised for $60B Market by 2031 as 550+ Trials Reshape Therapeutics

Bispecific antibody market projected to reach $60 billion by 2031 from $16 billion in 2025, with 550+ clinical trials and 18 approved drugs driving sector transformation.
AMGNJNJPFEABBVRHHBY+3clinical trialsautoimmune diseases
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Drug Development Services Market Set to Double to $50B by 2030

Drug development services market projected to reach $50.26B by 2030 from $28.09B in 2025, driven by AI adoption, personalized medicine, and emerging market expansion.
CRLIQVLZAGYLHWUXAYregulatory complianceclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Atopic Dermatitis Market Set to Soar 143% to $26.2B by 2033

Global atopic dermatitis market projected to grow from $10.8B in 2023 to $26.2B by 2033, driven by seven late-stage pipeline drugs and expanded treatment options.
AMGNPFEABBVLLYSNY+1drug developmentatopic dermatitis
The Motley FoolThe Motley Fool··Thomas Niel

Viking Therapeutics' VK2735 Could Reshape Weight Loss Market—If Phase 3 Succeeds

Viking Therapeutics' VK2735 could threaten Novo Nordisk and Eli Lilly's GLP-1 dominance if phase 3 trials succeed, triggering potential threefold gains or severe losses.
PFELLYNVOVKTXclinical trialsVK2735
Investing.comInvesting.com··Jeffrey Neal Johnson

Eli Lilly's $3B China Bet: Securing GLP-1 Dominance in World's Largest Metabolic Market

Eli Lilly commits $3 billion to decade-long China expansion, targeting 141 million diabetics and 600 million overweight adults amid intense domestic competition.
LLYNVOsupply chainGLP-1 drugs
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

GLP-1 Drug Market Poised to Triple to $202B by 2033 Amid Obesity Surge

Global GLP-1 receptor agonist market projected to grow from $70B in 2025 to $202B by 2033 at 12.78% annual rate, driven by obesity and diabetes prevalence.
LLYSNYNVOAZNIVBIYclinical trialsmarket growth